Related Experiment Videos
Acute promyelocytic leukemia: a view from a mouse
1Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143-0128, USA. skogan@cc.ucsf.edu
Blood Cells, Molecules & Diseases
|May 19, 2001
Summary
Murine models of acute promyelocytic leukemia (APL) are crucial for understanding cancer pathogenesis and developing novel therapies. These models, like the MRP8-PMLRARalpha transgenic mice, exhibit APL features and aid in identifying new therapeutic targets.
Area of Science:
- Oncology
- Hematology
- Molecular Biology
Background:
- Murine models are essential for studying human neoplasms and advancing cancer treatments.
- Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML).
Purpose of the Study:
- To utilize the MRP8-PMLRARalpha transgenic mouse model to study APL pathogenesis.
- To elucidate the role of PMLRARalpha in leukemia development.
- To identify cooperating genetic changes and novel molecular targets for APL therapy.
Main Methods:
- Development and utilization of MRP8-PMLRARalpha transgenic mice.
- Characterization of leukemias developed in these mice.
- Analysis of APL features including responsiveness to retinoic acid and arsenic.
Main Results:
- The MRP8-PMLRARalpha transgenic mouse model successfully mimics human APL characteristics.
- This model aids in understanding how PMLRARalpha contributes to leukemia.
- The model helps identify genetic alterations that cooperate in leukemia development.
Conclusions:
- APLs and other AMLs arise from genetic changes impairing cell differentiation and promoting survival.
- Retinoic acid is a key therapeutic target for APL, improving patient survival.
- Targeted therapies aimed at restoring maturation or controlling proliferation offer hope for AML treatment.